nasdaq:lxrx
|
10186
|
Mar 23rd, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
411.00
|
Open
|
|
Mar 22nd, 2024 11:53PM
|
Mar 23rd, 2024 07:02PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 22nd, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
411.00
|
Open
|
|
Mar 21st, 2024 11:43PM
|
Mar 22nd, 2024 06:50PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 21st, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
411.00
|
Open
|
|
Mar 20th, 2024 11:56PM
|
Mar 21st, 2024 05:34PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 20th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
410.00
|
Open
|
|
Mar 20th, 2024 12:37AM
|
Mar 20th, 2024 07:35PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 19th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
410.00
|
Open
|
|
Mar 18th, 2024 11:31PM
|
Mar 19th, 2024 06:07PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 18th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
410.00
|
Open
|
|
Mar 17th, 2024 11:53PM
|
Mar 18th, 2024 07:19PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 17th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
411.00
|
Open
|
|
Mar 17th, 2024 01:40AM
|
Mar 17th, 2024 01:40AM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 16th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
411.00
|
Open
|
|
Mar 15th, 2024 11:22PM
|
Mar 16th, 2024 07:06PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 15th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
412.00
|
Open
|
|
Mar 15th, 2024 12:54AM
|
Mar 15th, 2024 08:56AM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:lxrx
|
10186
|
Mar 14th, 2024 12:00AM
|
Lexicon Pharmaceuticals, Inc.
|
18K
|
412.00
|
Open
|
|
Mar 13th, 2024 11:20PM
|
Mar 14th, 2024 12:17PM
|
Corporate Overview
Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications.
The Genome: Our Source of Discovery
We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients.
A Diverse Pipeline of Targeted Therapies
Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.
|
Open
|
biopharma, knockout, novel drug, innovation, disease, and pharmaceutical
|
Open
|
8800 Technology Forest
|
The Woodlands
|
TX
|
US
|
77381
|
|
Lexicon Pharmaceuticals
|
Health Care
|
Pharmaceuticals & Biotechnology
|